---
schema_version: "secwatch.filing_event.v1"
accession: "0000899923-22-000009"
form_type: "8-K"
ticker: "MYGN"
cik: "0000899923"
company_name: "MYRIAD GENETICS INC"
filed_at: "2022-01-11T23:59:59+00:00"
generated_at: "2026-06-27T19:08:42.275941+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "medium"
source: SEC EDGAR
---

# Myriad Genetics expects ~$400M cash on hand, no debt entering 2022

## Summary
- CEO Paul Diaz presented at 40th Annual J.P. Morgan Health Care Conference on Jan 11, 2022.
- Company expects to start 2022 with approximately $400M in cash, cash equivalents, and marketable securities.
- Preliminary unaudited FY2021 financial data not finalized; adjustments could be material.
- Company reports no debt, highlighting strong liquidity position.

## SEC filing metadata
- accession: 0000899923-22-000009
- form_type: 8-K
- ticker: MYGN
- cik: 0000899923
- company_name: MYRIAD GENETICS INC
- filed_at: 2022-01-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: medium
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/899923/000089992322000009/0000899923-22-000009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/899923/000089992322000009/mygn-20220111.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000899923-22-000009
- JSON: https://secwatch.observer/filing/0000899923-22-000009.json
- Plain text: https://secwatch.observer/filing/0000899923-22-000009.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.